Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2193 • 2012 ACR/ARHP Annual Meeting
Validity of Low Titers of SSA/B Antibodies in Predicting A Key Feature of Sjögren’s Syndrome
Mara McAdams DeMarco¹, Mi Y. Lam², Stephen Shiboski², Lindsey A. Criswell³, Caroline Shiboski⁴ and Alan N. Baer⁵, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²University of California, San Francisco, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁴Orofacial Sciences, University of California, San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The validity of low titers of SSA and/or SSB (SSA/B) antibodies (Ab) in the diagnosis of Sjögren’s syndrome (SS) has not been defined. We…
Abstract Number: 525 • 2012 ACR/ARHP Annual Meeting
Gene Expression Profiling in a Large Cohort of Europeans with Sjögren’s Syndrome Reveals Candidate Genes in Viral, Immune, and Interferon-Related Pathways
He Li¹, John A. Ice², Jennifer A. Kelly³, Indra Adrianto², Stuart B. Glenn⁴, Kimberly S. Hefner⁵, Evan G. Vista⁶, Donald U. Stone⁷, Raj Gopalakrishnan⁸, Glen D. Houston⁹, David M. Lewis¹⁰, Michael Rohrer⁸, Pamela Hughes⁸, John B. Harley¹¹, Courtney G. Montgomery², James Chodosh⁷, James A. Lessard¹², Juan-Manuel Anaya¹³, Barbara M. Segal¹⁴, Nelson L. Rhodus¹⁵, Lida Radfar¹⁶, Mark B. Frank¹⁷, R. Hal Scofield¹⁸, Christopher J. Lessard¹⁹ and Kathy Moser Sivils³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ⁷Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁹Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Valley Bone and Joint Clinic, Grand Forks, ND, ¹³School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ¹⁴Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS), characterized by lymphocytic infiltration of exocrine glands, is a progressive autoimmune exocrinopathy present in 0.7-1% of Europeans. To better understand the…
Abstract Number: 2197 • 2012 ACR/ARHP Annual Meeting
Diagnostic Value of Blood B-Cell Subset Profiling and Autoimmunity Markers in Anti-SSA-Negative Sjögren’s Syndrome Patients
Divi Cornec¹, Alain Saraux², Jacques-Olivier Pers³, Sandrine Jousse-Joulin⁴, Yves Renaudineau³, Thierry Marhadour⁵ and Valerie Devauchelle-Pensec⁶, ¹Department of rheumatology, Brest Occidentale University, Brest, France, ²Department of rheumatology and unit of immunology (EA 2216), Brest Occidentale university, Brest, France, ³Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ⁴Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, ⁵Rheumatology, CHU de la Cavale Blanche, Brest, France, ⁶Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France
Background/Purpose: Recently published ACR classification criteria for primary Sjögren’s syndrome (pSS) suggest considering antinuclear antibodies (ANA) titer and rheumatoid factor (RF) positivity in patients negative…
Abstract Number: 526 • 2012 ACR/ARHP Annual Meeting
Use of a Novel Probe to Demonstrate Granzyme B Activity in Sjogren’s Syndrome Salivary Glands
Kimberly Doering Maurer¹, Laura Gutierrez-Alamillo¹, Efstathia K. Kapsogeorgou², Athanasios G. Tzioufas³, Livia Casciola-Rosen⁴ and Antony Rosen⁴, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ³Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁴Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Salivary glands are a prominent target organ in Sjögren’s syndrome (SS), with patients having abnormal secretory function and inflammatory infiltration of these glands. Little…
Abstract Number: 2201 • 2012 ACR/ARHP Annual Meeting
Involvement of Interleukin-33 in the Pathogenesis of Sjögren’s Syndrome
Ahmad Awada, Valérie Gangji and Muhammad S. Soyfoo, Rheumatology, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium
Background/Purpose: To investigate the role of IL-33/ST2 in the pathophysiology of primary Sjögren’s syndrome (pSS) Methods: Serum levels of IL-33 and sST2 was determined by…
Abstract Number: 528 • 2012 ACR/ARHP Annual Meeting
Mxa As a Biomarker for Systemic Interferon Type I Activation in Primary Sjögren′s Syndrome
Naomi I. Maria¹, Zana Brkic¹, Matti Waris², Cornelia G. van Helden-Meeuwsen¹, Kim Heezen¹, Joop P. van de Merwe¹, Paul L. van Daele³, Virgil A. Dalm³, Hemmo A. Drexhage³ and Marjan A. Versnel³, ¹Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Department of Virology, University of Turku, Turku, Finland, ³Erasmus Medical Center, Immunology, Rotterdam, Netherlands
Background/Purpose: To establish an easy and practical assay for detection of systemic Interferon (IFN) type I activation in primary Sjögren's syndrome (pSS). The monocyte IFN…
Abstract Number: 2177 • 2012 ACR/ARHP Annual Meeting
The Forced Oscillation Technique Is a Sensitive Method for Detection of Obstructive Airway Disease in Patients with Primary Sjögren’s Syndrome
Anna M. Nilsson¹, Elke Theander², Roger Hesselstrand³, Per Wollmer⁴ and Thomas Mandl⁵, ¹Dept of Rheumatology, Skane University Hospital Malmo, Lund University, Malmo, Sweden, ²Dept of Rheumatology, Skane University Hospital Malmo, Lund University, Malmö, Sweden, ³Rheumatology, Lund University, Lund, Sweden, ⁴Dept of Clinical Physiology, Skane University Hospital Malmo, Lund University, Malmö, Sweden, ⁵Dept of Rheumatology, Skåne University Hospital Malmo, Lund University, Sweden, Malmö, Sweden
Background/Purpose: To study signs of obstructive airway disease in patients with primary Sjögren’s syndrome (pSS) by the forced oscillation technique (FOT), a method that may…
Abstract Number: 529 • 2012 ACR/ARHP Annual Meeting
The Axis P2X7 Receptor-Inflammasome: A Role in Modulating Inflammatory Response in Primary Sjögren’s Syndrome?
Chiara Baldini¹, Chiara Rossi¹, Eleonora Santini¹, Francesco Ferro¹, Alessia Gallo², Daniela Martini¹, Francesca Sernissi¹, Valentina Donati¹, Camillo Giacomelli¹, Nicoletta Luciano¹, Anna Solini¹ and Stefano Bombardieri¹, ¹Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ²Sjogren's Clinic, NIDCR, Bethesda, MD
Background/Purpose: The exact cause of exocrine gland dysfunction in primary Sjögren’s syndrome (pSS) has not been fully delineated, but it is thought that both innate…
Abstract Number: 2181 • 2012 ACR/ARHP Annual Meeting
Concomitant Atheosclerosis and Impaired Bone Health in Patients with Primary Sjogren’s Syndrome
Clio P. Mavragani¹, Fotini Gravani², Andrianos Nezos¹, Eleni Antypa³, Kiki Maselou⁴, Dimitrios Ioakeimidis⁵, Michael Koutsilieris¹ and Haralampos M. Moutsopoulos⁶, ¹Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ²Department of Rheumatology, General Hospital of Athens "G.Gennimatas", Athens, Greece, ³Department of Radiology, General Hospital of Athens, Greece, ⁴Department of Immunolgy, General Hospital of Athens, Greece, ⁵Department of Rheumatology, General Hospital of Athens "G.Gennimatas", Greece, Greece, ⁶Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece
Background/Purpose: To determine the prevalence of subclinical atherosclerosis and impaired bone health in primary Sjogren’s syndrome (pSS) patients and to explore whether they associate with…
Abstract Number: 504 • 2012 ACR/ARHP Annual Meeting
Pathogenic Autoantibodies to the Anti-Muscarinic Type 3 Receptor Act by Competitive Inhibition of Acetylcholine-Mediated Receptor Signalling in Sjögren’s Syndrome
Michael W. Jackson¹, Isabell Bastian² and Thomas P. Gordon³, ¹Immunology, Flinders University, Adelaide, Australia, ²Immunology, Allergy and Arthritis, Flinders University and Flinders Medical Centre, Adelaide, Australia, ³Immunology Allergy & Arthritis, Flinders Medical Centre, Bedford Park, Australia
Background/Purpose: Primary Sjögren’s syndrome (SS) is a systemic autoimmune disorder characterized by exocrine failure and widespread autonomic dysfunction. Functional autoantibodies (Abs) directed against the muscarinic…
Abstract Number: 1487 • 2012 ACR/ARHP Annual Meeting
Incidence of Fibromyalgia Syndrome in Systemic Sclerosis and Rheumatoid Arthritis. Comparative Results According to Clinical Diagnosis, Screening Test with Fibromyalgia Rapid Screening Tool, Diagnosis with ACR1990 and ACR 2010 Criteria
Serge Perrot¹, Mariana Peixoto², Philippe Dieude³, Eric Hachulla⁴, Sébastien Ottaviani⁵ and Yannick Allanore⁶, ¹Internal Medicine and Pain Clinic, Hopital Hotel Dieu, Paris, France, ²Rheumatology Department, Cochin Hospital, Paris, France, ³Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ⁴Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ⁵Service de Rhumatologie, Hôpital Bichat, APHP, APHP, Paris, France, ⁶Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France
Background/Purpose: Fibromyalgia (FMS) is a chronic widespread pain condition that may be associated with inflammatory chronic disorders like rheumatoid arthritis (RA) and systemic sclerosis (SSc).…
Abstract Number: 506 • 2012 ACR/ARHP Annual Meeting
Ebv-Mir-Bart13 Affects the Expression of AQP5 in Human Salivary Gland Cell Lines Contributing to the Pathogenesis of Sjögren’s Syndrome
Alessia Gallo¹, Mayank Tandon¹, Shyh-Ing Jang², Hwei Ling Ong², Indu Ambudkar², Gabor G. Illei³ and Ilias Alevizos⁴, ¹Sjogren's Clinic, NIDCR, Bethesda, MD, ²Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, ³Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, ⁴Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD
Background/Purpose: Loss of secretory function of salivary glands is one of the most important functional effects of Sjögren’s syndrome (SS), a chronic systemic autoimmune disease.…
Abstract Number: 530 • 2012 ACR/ARHP Annual Meeting
S100A8/A9 Is Upregulated and Triggers the Secretion of Pro-Inflammatory Cytokines in Primary Sjögren’s Syndrome
Laura Weichselbaum¹ and Muhammad S. Soyfoo², ¹Rheumatology, Department of rheumatology ,Hôpital Erasme, Brussels, Belgium, ²Rheumatology, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium
Background/Purpose: To determine the involvement of S100A8/A9 in the pathogenesis of primary Sjögren’s syndrome (pSS) Methods: The serum levels of S100A8/A9, IL-17A and IL-17C were…
Abstract Number: 508 • 2012 ACR/ARHP Annual Meeting
TLR3-Signaling Induces the Expression of Ro/SSA and La/SSB Autoantigens in Salivary Gland Epithelial Cells (SGECs)
Nikolaos C. Kyriakidis¹, Efstathia K. Kapsogeorgou¹, Vasiliki C. Gourzi¹, Haralampos M. Moutsopoulos² and Athanasios G. Tzioufas³, ¹Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ²Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ³Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Previous studies have shown that the mRNA expression levels of the Ro52/TRIM21, Ro60/TROVE2 and La/SSB intracellular autoantigens are elevated within the immunopathologic lesions of…
Abstract Number: 510 • 2012 ACR/ARHP Annual Meeting
IL-7 and IL-7 Receptor Blockade to Selectively Inhibit TLR7-Induced B Cell Activation in Primary Sjögren’s Syndrome
A. Bikker¹, C.R. Willis², A.a. Kruize¹, J.W.J. Bijlsma³, F.P.J.G. Lafeber³ and J.A.G. van Roon⁴, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Amgen Inc., Seattle, WA, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Toll-like receptors (TLRs) are involved in the recognition of nucleic acids (viral, bacterial, and possibly self) and have been implicated in several auto-immune diseases.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].